Kiran Mazumdar Shaw Solidifies Biocon Legacy With US Family

Claire Mazumdar

BOSTON, MA – Kiran Mazumdar-Shaw, founder of biopharmaceutical company Biocon, has named her niece Claire Mazumdar as her successor, outlining a formal succession plan for the company, according to a report published on May 5.

The 73-year-old entrepreneur said she sees Claire Mazumdar, 37, as the right person to lead Biocon into its next phase of growth. “I am the sole owner of Biocon, and I need to make sure that I put it in good hands. I have seen my niece Claire as my successor because I think she has proved to me that she can run a company,” she said.

Claire is the founder and CEO of Boston based Bicara Therapeutics, a Nasdaq-listed company incubated by Biocon. Kiran Mazumdar-Shaw, who has no children, also said a broader family ecosystem could help support the company’s future growth.

She referred to Claire Mazumdar’s brother, Eric Mazumdar, a professor at the California Institute of Technology and an artificial intelligence expert, as well as Claire’s husband Thomas Roberts, an oncologist at Massachusetts General Hospital.

As part of a wider organizational overhaul, Biocon has merged its generics and biologics businesses, simplified its structure, and reduced debt, the report said. The company is sharpening its focus on biosimilars, which contribute a significant share of revenue, with several products already in the market and more in the pipeline, Kiran Mazumdar-Shaw said.

Claire Mazumdar holds a degree in Biological Engineering from the Massachusetts Institute of Technology, an MBA from Stanford Graduate School of Business, and a PhD in Cancer Biology from Stanford School of Medicine. (IANS)